Last reviewed · How we verify
Ketotifen Fumarate 0.25% Cream — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Ketotifen Fumarate 0.25% Cream (Ketotifen Fumarate 0.25% Cream) — Center for Vulvovaginal Disorders.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ketotifen Fumarate 0.25% Cream TARGET | Ketotifen Fumarate 0.25% Cream | Center for Vulvovaginal Disorders | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ketotifen Fumarate 0.25% Cream CI watch — RSS
- Ketotifen Fumarate 0.25% Cream CI watch — Atom
- Ketotifen Fumarate 0.25% Cream CI watch — JSON
- Ketotifen Fumarate 0.25% Cream alone — RSS
Cite this brief
Drug Landscape (2026). Ketotifen Fumarate 0.25% Cream — Competitive Intelligence Brief. https://druglandscape.com/ci/ketotifen-fumarate-0-25-cream. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab